Efficacy and time to next treatment following lenalidomide/rituximab (R2) or rituximab/placebo in patients with R/R indolent NHL (AUGMENT).

John G. Gribben,Koji Izutsu,Nathan Fowler,Xiaonan Hong,Huilai Zhang,Fritz Offner,Adriana Scheliga,Grzegorz S. Nowakowski,Antonio Pinto,Francesca Re,Laura Fogliatto,Phillip Scheinberg,Ian W. Flinn,Claudia Moreira,Stacey Kalambakas,Pierre Fustier,Chengqing Wu,John P. Leonard

Efficacy and time to next treatment following lenalidomide/rituximab (R2) or rituximab/placebo in patients with R/R indolent NHL (AUGMENT).

2019

John G. Gribben
Koji Izutsu
Nathan Fowler
Xiaonan Hong
Huilai Zhang
Fritz Offner
Adriana Scheliga
Grzegorz S. Nowakowski
Antonio Pinto
Francesca Re
Laura Fogliatto
Phillip Scheinberg
Ian W. Flinn
Claudia Moreira
Stacey Kalambakas
Pierre Fustier
Chengqing Wu
John P. Leonard

7514Background: Relapse is expected in treated indolent lymphoma patients, and an unmet need exists to prolong remission with effective therapies. Lenalidomide + rituximab (R2) may improve the effi...

Keywords:

Lenalidomide
Augment
Pathology
Placebo
Rituximab
Lymphoma
Oncology
Internal medicine
Lenalidomide/rituximab
Medicine
in patient
Physical therapy
unmet needs
time to next treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations